Literature DB >> 27440204

A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Mona Aarenstrup Karlsen1,2, Carsten Fagö-Olsen3, Estrid Høgdall4, Tine Henrichsen Schnack3, Ib Jarle Christensen4, Lotte Nedergaard5, Lene Lundvall3, Magnus Christian Lydolph6, Svend Aage Engelholm7, Claus Høgdall3.   

Abstract

The purpose of this study was to develop a novel index for preoperative, non-invasive prediction of complete primary cytoreduction in patients with FIGO stage IIIC-IV epithelial ovarian cancer. Prospectively collected clinical data was registered in the Danish Gynecologic Cancer Database. Blood samples were collected within 14 days of surgery and stored by the Danish CancerBiobank. Serum human epididymis protein 4 (HE4), serum cancer antigen 125 (CA125), age, performance status, and presence/absence of ascites at ultrasonography were evaluated individually and combined to predict complete tumor removal. One hundred fifty patients with advanced epithelial ovarian cancer were treated with primary debulking surgery (PDS). Complete PDS was achieved in 41 cases (27 %). The receiver operating characteristic curves demonstrated an area under the curve of 0.785 for HE4, 0.678 for CA125, and 0.688 for age. The multivariate model (Cancer Ovarii Non-invasive Assessment of Treatment Strategy (CONATS) index), consisting of HE4, age, and performance status, demonstrated an AUC of 0.853. According to the Danish indicator level, macro-radical PDS should be achieved in 60 % of patients admitted to primary surgery (positive predictive value of 60 %), resulting in a negative predictive value of 87.5 %, sensitivity of 68.3 %, specificity of 83.5 %, and cutoff of 0.63 for the CONATS index. Non-invasive prediction of complete PDS is possible with the CONATS index. The CONATS index is meant as a supplement to the standard preoperative evaluation of each patient. Evaluation of the CONATS index combined with radiological and/or laparoscopic findings may improve the assessment of the optimal treatment strategy in patients with advanced epithelial ovarian cancer.

Entities:  

Keywords:  HE4; Multidisciplinary team meetings; Neoadjuvant chemotherapy; Non-invasive prediction model; Ovarian cancer; Primary debulking surgery

Mesh:

Substances:

Year:  2016        PMID: 27440204     DOI: 10.1007/s13277-016-5166-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Diagnostic open laparoscopy in the management of advanced ovarian cancer.

Authors:  Roberto Angioli; Innocenza Palaia; Marzio Angelo Zullo; Ludovico Muzii; Natalina Manci; Marco Calcagno; Pierluigi Benedetti Panici
Journal:  Gynecol Oncol       Date:  2005-12-01       Impact factor: 5.482

Review 2.  Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer.

Authors:  Marianne J Rutten; Mariska M G Leeflang; Gemma G Kenter; Ben Willem J Mol; Marrije Buist
Journal:  Cochrane Database Syst Rev       Date:  2014-02-21

3.  The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.

Authors:  T S Barlow; M Przybylski; J M Schilder; D H Moore; K Y Look
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

4.  Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings.

Authors:  Ha-Jeong Kim; Chel Hun Choi; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  Taiwan J Obstet Gynecol       Date:  2014-09       Impact factor: 1.705

5.  A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  O Gemer; M Lurian; M Gdalevich; V Kapustian; E Piura; D Schneider; O Lavie; T Levy; A Fishman; R Dgani; H Levavi; U Beller
Journal:  Eur J Surg Oncol       Date:  2005-07-07       Impact factor: 4.424

6.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.

Authors:  R E Bristow; L R Duska; N C Lambrou; E K Fishman; M J O'Neill; E L Trimble; F J Montz
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

7.  Factors associated with cytoreducibility among women with ovarian carcinoma.

Authors:  Gamal H Eltabbakh; Sharon L Mount; Barbara Beatty; Linda Simmons-Arnold; Kumarasen Cooper; Anne Morgan
Journal:  Gynecol Oncol       Date:  2004-11       Impact factor: 5.482

8.  Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

Authors:  Carsten Lindberg Fagö-Olsen; Bent Ottesen; Henrik Kehlet; Sofie L Antonsen; Ib J Christensen; Algirdas Markauskas; Berit J Mosgaard; Christian Ottosen; Charlotte H Soegaard; Erik Soegaard-Andersen; Claus Hoegdall
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

9.  Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?

Authors:  Roberto Angioli; Francesco Plotti; Stella Capriglione; Alessia Aloisi; Roberto Montera; Daniela Luvero; Andrea Miranda; Ester Valentina Cafà; Patrizio Damiani; Pierluigi Benedetti-Panici
Journal:  Gynecol Oncol       Date:  2012-12-07       Impact factor: 5.482

10.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

View more
  8 in total

Review 1.  Prediction of optimal debulking surgery in ovarian cancer.

Authors:  Yong Jung Song
Journal:  Gland Surg       Date:  2021-03

Review 2.  The Significance of Peritoneal Washing as a Prognostic Indicator for Ovarian Cancer Patients.

Authors:  Christina Christou; Sevasti-Effraimia Krouskou; Antonios Koutras; Thomas Ntounis; Zacharias Fasoulakis; Asimina Valsamaki; Vasilios Pergialiotis; Sotirios Sotiriou; Kyriakos Konis; Panagiotis Symeonidis; Athina A Samara; Athanasios Pagkalos; Athanasios Chionis; Georgios Daskalakis; Emmanuel N Kontomanolis
Journal:  Cancer Diagn Progn       Date:  2022-09-03

3.  Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer

Authors:  Maliheh Arab; Farzaneh Jamdar; Maryam Sadat Hosseini; Robabe Ghodssi- Ghasemabadi; Farah Farzaneh; Tahereh Ashrafganjoei
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

4.  The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.

Authors:  Ga Won Yim; Dong Hoon Suh; Jae Weon Kim; Seung Cheol Kim; Young Tae Kim
Journal:  J Gynecol Oncol       Date:  2019-07       Impact factor: 4.401

5.  Prognostic Significance of Log(CA125)/PCI for the Resectability of Epithelial Ovarian Cancer: A Retrospective Study.

Authors:  Can He; Niresh Thapa; Yang Wang; Ziye Song; Jing Yang; Mengfei Xu; Na Zuo; Hongbing Cai
Journal:  Cancer Manag Res       Date:  2020-03-25       Impact factor: 3.989

6.  Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer.

Authors:  Robert Bachmann; Sara Brucker; Annette Stäbler; Bernhard Krämer; Ruth Ladurner; Alfred Königsrainer; Diethelm Wallwiener; Cornelia Bachmann
Journal:  Mol Clin Oncol       Date:  2020-11-12

7.  Preoperative Predictors of Optimal Tumor Resectability in Patients With Epithelial Ovarian Cancer.

Authors:  Kehinde S Okunade; Adaiah P Soibi-Harry; Benedetto Osunwusi; Ephraim Ohazurike; Sarah O John-Olabode; Adeyemi Okunowo; Garba Rimi; Omolola Salako; Muisi Adenekan; Rose Anorlu
Journal:  Cureus       Date:  2022-01-19

8.  Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project.

Authors:  Julie L Hentze; Claus Høgdall; Susanne K Kjær; Jan Blaakær; Estrid Høgdall
Journal:  Contemp Clin Trials Commun       Date:  2017-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.